Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C6H5O7.3Mg |
Molecular Weight | 451.1144 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].[Mg++].[Mg++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=PLSARIKBYIPYPF-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Mg/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6
Molecular Formula | C6H5O7 |
Molecular Weight | 189.0997 |
Charge | -3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium
phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.
CNS Activity
Sources: DOI: 10.1002/0471238961.0218151310010311.a02Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQChttps://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors. | 1977 Apr |
|
Characterization of the prolactin receptor in human prostate. | 1983 Nov |
|
Symptomatic hypercalcaemia precipitated by magnesium therapy. | 1985 Jan |
|
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes. | 1986 Sep |
|
Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. | 1988 Sep 1 |
|
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium]. | 1989 Sep |
|
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain. | 1990 Feb 5 |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Overexpressed protein kinase C-delta and -epsilon subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake. | 1994 Feb 18 |
|
Cocaine-induced cerebrovasospasm and its possible mechanism of action. | 1994 Mar |
|
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid. | 1995 Mar |
|
The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. | 2004 Aug |
|
Major and trace elements in whole blood of phlebotomized patients with porphyria cutanea tarda. | 2005 |
|
Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. | 2005 Oct |
|
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. | 2005 Oct |
|
Pretreatment with magnesium sulphate is associated with less succinylcholine-induced fasciculation and subsequent tracheal intubation-induced hemodynamic changes than precurarization with vecuronium during rapid sequence induction. | 2006 |
|
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain. | 2006 Apr 25 |
|
Further characterization of mammalian ceramide kinase: substrate delivery and (stereo)specificity, tissue distribution, and subcellular localization studies. | 2006 Feb |
|
Structure of pyrimidine 5'-nucleotidase type 1. Insight into mechanism of action and inhibition during lead poisoning. | 2006 Jul 21 |
|
Activation and enzymatic characterization of recombinant human kallikrein 8. | 2006 Jun |
|
Evidence for a two-step mechanism involved in the formation of covalent HC x TSG-6 complexes. | 2006 Jun 20 |
|
Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. | 2006 Mar |
|
Uncompetitive inhibition of Xenopus laevis aldehyde dehydrogenase 1A1 by divalent cations. | 2006 Mar |
|
The expression of genes for transepithelial calcium-transporting proteins in the bovine duodenum. | 2006 Mar |
|
Kinetic properties of chimeric class I aldehyde dehydrogenases for retinal isomers. | 2006 Oct |
|
The specific, submicromolar-Km ADP-ribose pyrophosphatase purified from human placenta is enzymically indistinguishable from recombinant NUDT9 protein, including a selectivity for Mn2+ as activating cation and increase in Km for ADP-ribose, both elicited by H2O2. | 2006 Oct |
|
Divalent-metal-dependent nucleolytic activity of Cu, Zn superoxide dismutase. | 2006 Oct |
|
Multivariate analysis of the selected metals in the hair of cerebral palsy patients versus controls. | 2006 Summer |
|
Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and beta-adrenergic desensitization. | 2007 Mar |
|
Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. | 2007 Nov |
|
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007 Sep |
|
The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. | 2007 Sep |
|
[The characterization of central neuromediation in rats fed with magnesium-deprived diet before and after magnesium replenishment]. | 2008 Jul |
|
Interactions between magnesium and psychotropic drugs. | 2008 Jun |
|
Treatment of migraine with prophylactic drugs. | 2008 Oct |
|
Cocaine use disorders and serum magnesium profile. | 2009 |
|
Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. | 2009 Dec |
|
Differential binding of inorganic particles to MARCO. | 2009 Jan |
|
AZT-induced oxidative cardiovascular toxicity: attenuation by Mg-supplementation. | 2009 Jun |
|
The loop connecting metal-binding domains 3 and 4 of ATP7B is a target of a kinase-mediated phosphorylation. | 2009 Jun 23 |
|
Evidence that TRPM7 is required for breast cancer cell proliferation. | 2009 Sep |
|
Hair tissue mineral analysis and metabolic syndrome. | 2009 Sep |
|
Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). | 2010 Apr 13 |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. | 2011 Feb |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition. | 2011 Feb |
|
Millimolar Mn2+ influences agonist binding to 5-HT1A receptors by inhibiting guanosine nucleotide binding to receptor-coupled G-proteins. | 2011 Jan |
|
Hypoxia induces an increase in intracellular magnesium via transient receptor potential melastatin 7 (TRPM7) channels in rat hippocampal neurons in vitro. | 2011 Jun 10 |
|
NADH fluorescence lifetime analysis of the effect of magnesium ions on ALDH2. | 2011 May 30 |
|
Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1. | 2013 Feb 25 |
|
Catalytic contribution of threonine 244 in human ALDH2. | 2013 Feb 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27995243
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm
were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:06:43 GMT 2023
by
admin
on
Fri Dec 15 15:06:43 GMT 2023
|
Record UNII |
RHO26O1T9V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA12CC04
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
||
|
WHO-ATC |
B05CB03
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
||
|
WHO-VATC |
QA06AD19
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
||
|
WHO-VATC |
QB05CB03
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
||
|
WHO-ATC |
A06AD19
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
||
|
WHO-ATC |
A12CC04
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
||
|
DSLD |
2649 (Number of products:15)
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RHO26O1T9V
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
Magnesium Citrate
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
SUB14422MIG
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
52356
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000091252
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105061
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
MAGNESIUM CITRATE
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
RHO26O1T9V
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
3693607
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
1374259
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
DB11110
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
222-093-9
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
7779-25-1
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C110422
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
83517
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
4281
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
m6997
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
C1505
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
DTXSID601015151
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
3344-18-1
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
C29241
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
PRIMARY | |||
|
231-923-9
Created by
admin on Fri Dec 15 15:06:43 GMT 2023 , Edited by admin on Fri Dec 15 15:06:43 GMT 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS | |||
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |